ILMN

Business Context and Reporting Period

Company: ILLUMINA, INC.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: March 31, 2001
Business Overview: Illumina is an early-stage biotechnology company developing next-generation tools for large-scale genetic analysis, specifically its proprietary BeadArray technology. The company has no commercially available microarray products to date. Revenue is primarily derived from government grants (e.g., NIH) and strategic partnerships, notably with Applied Biosystems, with commercial product launch expected in mid-2002.

Key Financial Metrics

Debt & Liquidity: The company holds approximately $113.6 million in cash and cash equivalents. Total debt obligations include equipment notes totaling approximately $1.1 million. The company has an available equipment loan arrangement of $1.7 million.

Material Changes vs. Prior Period

• Revenue Growth: Revenue increased to $0.6 million from $0.1 million, driven primarily by government grants. The company commenced earning revenue from one of its acquired technology projects (oligonucleotide synthesis instrumentation) in Q1 2001.
• Expense Increases:
  • R&D Expenses: Increased to $4.5 million from $3.6 million due to increased staffing and personnel costs to support commercialization. Note: Q1 2000 included a $1.6 million non-recurring charge for in-process technology acquisition.
  • G&A Expenses: Increased to $1.2 million from $0.6 million, attributed to staffing increases and costs associated with being a public company.
• Interest Income: Net interest income rose significantly to $1.8 million from $0.5 million, reflecting higher average cash and investment balances.
• Stock-Based Compensation: Amortization of deferred compensation was $1.6 million in Q1 2001 compared to $1.2 million in Q1 2000.

Outlook, Risks, and Management Commentary

• Commercialization Timeline: The company expects to commercialize its first products under its partnership with Applied Biosystems in mid-2002. It currently relies on partners for sales, marketing, and instrument development.
• Liquidity Outlook: Management believes current cash, investments, and funding from alliances/grants are sufficient to fund operations for at least the next 24 months. However, additional funding may be required sooner depending on scientific progress and market conditions.
• Capital Expenditures: The company exercised an option in December 2000 to purchase new facilities. The purchase is expected to close in Q3 2001, at which time the company will assume a $24 million mortgage and pay remaining construction costs of $5.0–$7.0 million.
• Key Risks:
  • Profitability: The company expects to continue incurring net losses and increasing operating expenses. There is no guarantee of achieving profitability.
  • Manufacturing: Limited manufacturing experience; reliance on third-party suppliers for critical components (e.g., fiber optic bundles).
  • Partnership Dependency: Success is heavily dependent on the Applied Biosystems partnership. If the partner fails to deliver instruments or market products, Illumina's commercialization could be delayed or fail.
  • Market Acceptance: Target markets (SNP genotyping, gene expression) are emerging and unproven; competitors may develop superior technologies.

Investor Verification Checklist

• Verify the status and terms of the strategic partnership with Applied Biosystems, specifically regarding the mid-2002 product launch timeline.
• Confirm the closing date and final terms of the $24 million mortgage assumption for the new facilities expected in Q3 2001.
• Monitor the burn rate of cash reserves against the projected 24-month runway, given the expectation of increasing R&D and G&A expenses.
• Assess the progress of the three acquired technology projects (oligonucleotide and peptide synthesis) and their potential contribution to future revenue.
• Review the company's ability to secure supply chains for single-source components like fiber optic bundles.